<DOC>
	<DOCNO>NCT00531661</DOCNO>
	<brief_summary>This prospective , multi-center , randomize , single-blind clinical trial conduct United States ( US ) . The objective study evaluate safety efficacy HF Pressure Measurement System reduce heart failure ( HF ) relate hospitalization subset subject suffer HF .</brief_summary>
	<brief_title>CardioMEMS Heart Sensor Allows Monitoring Pressure Improve Outcomes NYHA Class III Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Diagnosis HF ≥ 3 month , either preserve reduced LVEF 2 . Diagnosis NYHA Class III HF ( historical assessment document screen visit ) 3 . Subjects reduce LVEF must receive beta blocker 3 month ACEI ARB one month unless investigator 's opinion , subject intolerant beta blocker , ACEI ARB . Beta blocker ACEI ( ARB ) dose stable one month prior study entry . 4 . At least 1 HF hospitalization within 12 month Screening Visit 5 . Subjects pulmonary artery branch diameter size 7mm 15mm ( implanted vessel ) 1 . Subjects history recurrent ( &gt; 1 ) pulmonary embolism deep vein thrombosis 2 . Subjects , Investigator 's opinion , unable tolerate right heart catheterization 3 . Subjects major cardiovascular event ( e.g. , myocardial infarction , stroke ) within 2 month Screening Visit 4 . Subjects Cardiac Resynchronization Device ( CRT ) implant ≤ 3 month prior enrollment 5 . Subjects Glomerular Filtration Rate ( GFR ) &lt; 25 ml/min nonresponsive diuretic therapy chronic renal dialysis 6 . Subjects likely undergo heart transplantation within 6 month Screening Visit 7 . Subjects congenital heart disease mechanical right heart valve ( ) 8 . Subjects know coagulation disorder 9 . Subjects hypersensitivity allergy aspirin , and/or clopidogrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>